BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//New York Institute of Food Technologists (NYIFT) - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://nyift.org
X-WR-CALDESC:Events for New York Institute of Food Technologists (NYIFT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241119T170000
DTEND;TZID=America/New_York:20241119T203000
DTSTAMP:20260405T091758
CREATED:20241010T170028Z
LAST-MODIFIED:20241023T022008Z
UID:46277-1732035600-1732048200@nyift.org
SUMMARY:GLP-1 Weight Loss Medications
DESCRIPTION:New York & Central New Jersey IFT Panel \n\n\n\nTargeted Opportunities for the Food and Supplement Industries\n\n\n\nThe GLP-1 medications phenomenon is expected to cover 10% of the global population and demand outpaces supply in many countries. The medically supported weight loss market is projected to reach up to $100 billion by 2030.  \n\n\n\nThese weight loss and diabetes control medications should be looked at as an opportunity more than a threat to the Food Industry. This event will be a panel presentation of 4 speakers and a moderator followed by Q&A with the audience.  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMeet the Moderator\n\n\n\nLaura Rokosz\, Ph.D.\, RDN\n\n\n\nPharmaceutical & Biotechnology Sectors \n\n\n\nRead Laura Rokosz’s Bio\n\nAs our Moderator\, Laura will introduce our other speakers and share her expertise as a Dietitian\, offering dietary recommendations for those undergoing treatment with GLP-1 mimetics. \n\n\n\nDr. Laura Rokosz is a Registered Dietitian Nutritionist (RDN) with 28 years of experience in the Pharmaceutical and Biotechnology sectors. \n\n\n\nShe earned her B.S.\, M.S.\, and Ph.D. in Food Science from Rutgers University and completed her RDN internship through the Rutgers Individual Supervised Practice Pathway (ISPP) Dietetics program. \n\n\n\nDr. Rokosz has worked with Schering-Plough\, Merck\, and Pharmacopeia\, contributing to research and development in drug development. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanelist\n\n\n\nDr. Colette Knight\, MD\n\n\n\nChair of Inserra Family Diabetes Institute \n\n\n\n\nRead Dr. Colette Knight’s Bio\n\nDr. Colette Knight serves as the chair of the Inserra Family Diabetes Institute and is the division director of Endocrinology\, Diabetes\, and Metabolism at Hackensack University Medical Center. Additionally\, she holds the position of associate professor of medicine at Hackensack Meridian School of Medicine. \n\n\n\nDr. Knight is devoted to assisting patients with diabetes and is focused on eliminating obstacles that hinder access to healthcare. With a wealth of experience as a clinician\, educator\, and researcher\, she is deeply committed to community outreach and education regarding endocrine and diabetes-related conditions.  \n\n\n\n\n\n\n\n\n\nGLP Agonists: A New Era in Obesity Management\n\n\n\nPanel Details\n\nDr. Knight will explore the various factors influencing obesity\, highlighting the significance of understanding the risk factors\, behaviors\, and mechanisms that contribute to its onset. \n\n\n\nShe will address innovative treatments\, including glucagon-like peptide receptor agonists (GLP-RA)\, for weight management\, whether used independently or alongside surgical interventions. \n\n\n\nThese treatments are linked to positive outcomes\, such as enhancements in dysglycemia and cardiovascular health. \n\n\n\nDr. Knight’s discussion will examine the relationship between metabolism and obesity\, detailing the mechanisms of action and appropriate indications for these novel therapies. Furthermore\, she will cover how these medications influence satiety and the nutritional and dietary support required for patients utilizing GLP-1 therapies. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanelist\n\n\n\nDr. Suketu Patel\, MD\, Ph.D.\n\n\n\nGlobal Chief Medical OfficerHavas Health Network \n\n\n\n\nRead Dr. Suketu Patel’s Bio\n\nDr. Patel holds the position of Global Chief Medical Officer at Havas Health Network\, where he is instrumental in spearheading the GLP-1 consultancy. He has effectively launched and rejuvenated a multitude of brands across a range of therapeutic domains\, including nutrition\, immunology\, oncology\, neurology\, genetics\, and rare diseases. Havas Health is dedicated to enhancing its partnerships with institutions and leveraging advanced data to promote effective communication in the contemporary marketplace. Through the GLP-1 consultancy\, Dr. Patel and Havas Health affirm their dedication to leading in this dynamic field. \n\n\n\n\n\n\n\n\n\nEvery Brand Needs a GLP-1 Strategy\n\n\n\nPanel Details\n\nThe ripple effect of GLP-1s across healthcare\, business\, & cultureParticipants will acquire knowledge regarding the impact of GLP-1s\, which\, through their varied mechanisms of action affecting multiple peripheral body systems\, can not only promote individual weight loss but also contribute to substantial weight loss at the population level. \n\n\n\nThis trend carries significant implications for a variety of related markets. GLP-1s are poised to initiate a ripple effect across three interrelated domains: healthcare (including diabetes\, obesity\, cardiology\, neurology\, hepatology\, and immunology)\, business (such as snack foods\, airlines\, fashion\, fitness\, and restaurants)\, and culture (covering social events\, dating\, and new hobbies). \n\n\n\nWithin these domains\, we propose a three-tier model to illustrate the potential influence of GLP-1s. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanelist\n\n\n\nJing Zhou\, Ph.D.\n\n\n\nSr. Manager in Nutrition\, Global Scientific & Regulatory AffairsIngredion \n\n\n\n\nRead Jing Zhou’s Bio\n\nDr. Jing Zhou serves as a Senior Manager in Nutrition within the Global Scientific and Regulatory Affairs division at Ingredion. She leverages her expertise in nutrition science to enhance both the existing product portfolio and innovation initiatives\, thereby fostering the growth of Ingredion’s Healthful Solutions sector. \n\n\n\nDr. Zhou earned her Ph.D. in Nutrition Science from Purdue University\, where she focused on clinical research related to human nutrition and medical devices. With a total of 14 years of experience in the field\, she possesses specialized knowledge in Clinical Nutrition\, dietary protein\, metabolic health\, sleep quality\, and skeletal muscle quality\, and has authored 19 research papers and abstracts. Additionally\, she holds certification as a Project Management Professional.  \n\n\n\n\n\n\n\n\n\nIngredient Solutions to Support Consumers in the Era of GLP-1 Receptor Agonists\n\n\n\nPanel Details\n\nThis presentation will explore ingredient solutions tailored for two primary consumer groups: those utilizing GLP-1 receptor agonists and those who are not but are interested in natural methods to enhance their satiety. For the first group\, it is essential to address concerns regarding potential lean body mass loss and associated side effects. \n\n\n\nConversely\, the second group may prioritize foods and diets that promote satiety and effective weight management. Potential ingredient solutions include dietary proteins\, fibers\, natural sweeteners\, and fat replacers\, among others.  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanelist\n\n\n\nLinda Zeitzoff MSN\, CRNP\, CDCES\n\n\n\nManager Medical Affairs – Metabolic HealthNestlé Health Science \n\n\n\n\nRead Linda Zeitzoff’s Bio\n\nLinda Zeitzoff is a nurse practitioner and certified diabetes care and education specialist with clinical experience managing children and young adults living with diabetes and obesity. Following clinical practice\, she spent 8 years in the pharmaceutical industry as a field-based educator for Novo Nordisk® where she engaged in conversations with health care providers\, patients\, payers and health system executives\, discussing the role GLP-1 medications play in diabetes and obesity management. \n\n\n\nCurrently\, Linda is a Medical Affairs Manager at Nestlé Health Science responsible for supporting the metabolic health portfolio of products through claims substantiation\, health care provider strategy and education\, consumer marketing and product innovation. \n\n\n\n\n\n\n\n\n\nNutritional Considerations in the Era of GLP-1 Medications for Weight Management\n\n\n\nPanel Details\n\nInsights and opportunities learned from consumers\, healthcare providers\, and scientific evidenceDuring this discussion\, attendees will gain a better understanding of the adult GLP-1 user after Linda presents consumer and healthcare professional data focusing on insights learned around attitudes and behaviors\, side-effects and lapse of medication use. \n\n\n\nLearn how Nestlé Health Science leveraged the data and scientific evidence to launch glp-1nutrition.com\, a new innovative web-based platform that supports the consumer with products\, tools and resources during their weight management journey. \n\n\n\nKey benefit areas to be highlighted include muscle preservation\, gut health\, micronutrient intake\, hydration\, skin and hair health and weight rebound. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBuy Tickets on Eventbrite\n\nBuy Tickets\n\n\n\n\n\n\n\nAdd to Calendar\n\n\n\n\n\n\n\nFees\n\n\n\n\nMembers – $55\n\n\n\nNon-Members – $60\n\n\n\nStudents\, Unemployed\, Retirees\, Executive Board – $30\n\n\n\n\n\n\nSchedule\n\n\n\n\n5-6 PM Networking & Cash Bar\n\n\n\n6-7:15 PM Dinner & Panel\n\n\n\n7:15-8:30 PM Dessert & Networking\n\n\n\n\n\nMenu\n\nSalad: \n\n\n\n\nLocal farm-fresh seasonal Caprese fruit salad with burrata cheese & crostini\n\n\n\n\nChoice of entree: \n\n\n\n\nPan seared Atlantic salmon basil grapefruit beurre blanc\n\n\n\n“Goffle Farm” Chicken scallopini sun-dried tomato\, artichoke\, chardonnay sauce\n\n\n\nVegetarian option (Chef’s Choice)\n\n\n\n\nDessert sampler plate: \n\n\n\n\nS’mores shooter\n\n\n\nMini apple cider donut\n\n\n\nCheesecake bite
URL:https://nyift.org/event/glp-1-weight-loss-medications/
LOCATION:Grain House\, 225 Morristown Rd\, Basking Ridge\, New Jersey\, 07920\, United States
CATEGORIES:CNJIFT,NYIFT,Panel
END:VEVENT
END:VCALENDAR